Does sacubitril/valsartan prevent subclinical cardiac dysfunction (GLS decline) in patients undergoing anthracycline-based chemotherapy?
Sacubitril/valsartan significantly reduces GLS decline, suggesting a protective role against subclinical cardiac dysfunction in patients receiving anthracycline-based chemotherapy.
This mini-review highlights the results of the SARAH trial, which evaluated the efficacy of sacubitril/valsartan in preventing subclinical cardiac dysfunction in patients undergoing anthracycline-based chemotherapy. The trial demonstrated a significant reduction in GLS decline in the treatment group compared to placebo. The findings are discussed in context with other trials investigating neurohormonal blockade for the prevention of cancer therapy-related cardiac dysfunction.
Mecinaj et al. (Mon,) studied this question.